아톨바스타틴과 니페디핀의 약물동태학적 상호작용
Pharmacokinetic Interaction Between Atorvastatin and Nifedipine
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The purpose of this study was to investigate the effect of atorvastatin on the pharmacokinetics of nifedipine (6 mg/kg)after oral administration of nifedipine with or without atorvastatin (0.5 and 2.0 mg/kg) in rats, and also was to evaluate to the effect of atorvastatin on the CYP3A4 activity. The 50% inhibiting concentration (IC50) values of atorvastatin on CYP3A4 activity is 46.1 μM. Atorvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner. Coadministration of atorvastatin increased significantly (p<0.05, 2.0 mg/kg) the plasma concentration-time curve (AUC)and the peak concentration (Cmax) of nifedipine compared to the control group. The relative bioavailability (RB%) of nifedipine was increased from 1.15- to 1.37-fold. Coadministration of atorvastatin did not significantly change the terminal half-life (T1/2) and the time to reach the peak concentration (Tmax) of nifedipine. Based on these results, we can make a conclusion that the significant changes of these pharmacokinetic parameters might be due to atorvastatin, which possesses the potency to inhibit the metabolizing enzyme (CYP3A4) in the liver and intestinal mucosa, and also inhibit the P-glycoprotein (P-gp) efflux pump in the intestinal mucosa. It might be suggested that atorvastatin altered disposition of nifedipine by inhibition of both the first-pass metabolism and P-glycoprotein efflux pump in the small intestine of rats. In conclusion, the presence of atorvastatin significantly enhanced the oral bioavailability of nifedipine, suggesting that concurrent use of atorvastatin with nifedipine should require close monitoring for potential drug interation.
Abstract
The purpose of this study was to investigate the effect of atorvastatin on the pharmacokinetics of nifedipine (6 mg/kg)after oral administration of nifedipine with or without atorvastatin (0.5 and 2.0 mg/kg) in rats, and also was to evaluate to the effect of atorvastatin on the CYP3A4 activity. The 50% inhibiting concentration (IC50) values of atorvastatin on CYP3A4 activity is 46.1 μM. Atorvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner. Coadministration of atorvastatin increased significantly (p<0.05, 2.0 mg/kg) the plasma concentration-time curve (AUC)and the peak concentration (Cmax) of nifedipine compared to the control group. The relative bioavailability (RB%) of nifedipine was increased from 1.15- to 1.37-fold. Coadministration of atorvastatin did not significantly change the terminal half-life (T1/2) and the time to reach the peak concentration (Tmax) of nifedipine. Based on these results, we can make a conclusion that the significant changes of these pharmacokinetic parameters might be due to atorvastatin, which possesses the potency to inhibit the metabolizing enzyme (CYP3A4) in the liver and intestinal mucosa, and also inhibit the P-glycoprotein (P-gp) efflux pump in the intestinal mucosa. It might be suggested that atorvastatin altered disposition of nifedipine by inhibition of both the first-pass metabolism and P-glycoprotein efflux pump in the small intestine of rats. In conclusion, the presence of atorvastatin significantly enhanced the oral bioavailability of nifedipine, suggesting that concurrent use of atorvastatin with nifedipine should require close monitoring for potential drug interation.
참고문헌 (34)
- Walter DG, "The first pass metabolism of nifedipine in man", Br J Clin Pharmacol, 18, pp.951~956 (1984)
- Raemsch KD, "Pharmacokinetics and metabolism of nifedipine", Hypertension, 5, pp.18~24 (1983)
- Henry PD, "Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem", Am J Cardiol, 46, pp.1047~1053 (1980)
- Sorkin E M, "A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders", Drugs, 30, pp.182~187 (1985)
- Guengerich FP, "Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4", J Med Chem, 4, pp.1838~1844 (1991)
- Iribarne C, "Interaction of methadone with substrates of human hepatic cytochrome P450 3A4", Toxicology, 117, pp.13~19 (1997)
- Watkins PB, "Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man", J Clin Invest, 80, pp.1029~1035 (1987)
- Kolars JC, "Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia", Gastroenterology, 102, pp.1186~1192 (1992)
- Gottesman MM, "Biochemistry of multidrug resistance mediated by the multidrug transporter", Annu Rev Biochem, 62, pp.385~390 (1993)
- Gan SL, "CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport", Drug Metab Dispos, 24, pp.344~350 (1996)
- Watkins PB, "The barrier function of CYP3A4 and Pglycoprotein in the small bowel", Adv Drug Deliv Rev, 27, pp.161~167 (1996)
- Wacher VH, "Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics", J Pharm Sci, 87, pp.1322~1328 (1998)
- Ito K, "Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach", Pharm Res, 16, pp.225~231 (1999)
- Chaudhary PM, "Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells", Cell, 66, pp.85~90 (1991)
- Van Asperen J, "Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker", Br J Cancer, 76, pp.1181~1187 (1997)
- Biedler JL, "Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies", Cancer Res, 30, pp.1174~1180 (1970)
- Ford JM, "Modulators of multidrug resistance preclinical studies", Hematol Oncol Clin N Am, 9, pp.337~342 (1995)
- Fruehauf JP, "Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression", Contrib Gynecol Obstet, 19, pp.39~45 (1994)
- Endo T, "Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK", Toxicol Appl Pharmacol, 185, pp.166~172 (2002)
- Hokama N, "Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats", J Pharm Pharmacol, 54, pp.821~826 (2002)
- Lea AP, "Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias", Drugs, 53, pp.828~847 (1997)
- Lennernas H, "Clinical pharmacokinetics of atorvastatin. Clin", Pharmacokinet, 42, pp.1141~1160 (2003)
- Boyd RA, "Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion", J Clin Pharmacol, 40, pp.91~98 (2000)
- Wu X, "Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter", Pharm Res, 17, pp.209~215 (2000)
- Holtzman CW, "Role of Pglycoprotein in Statin Drug Interactions", Pharmacotherapy, 26, pp.1601~1607 (2006)
- Mousa O, "The interaction of diltiazem with simvastatin", Clin Pharmacol Ther, 67, pp.267~74 (2000)
- Choi DH, "Effect of Atorvastatin on the Intravenous and Oral Pharmacokinetics of Verapamil in Rat", Biopharm Drug Dispos, 29, pp.45~50 (2008)
- Soon-Pyo Hong, "Effect of Atorvastatin on the Pharmacokinetics of Diltiazem and Its Main Metabolite, Desacetyldiltiazem, in Rats", Archives of Pharmacal Research, 30(1), pp.90~95 (2007), 대한약학회
- 최병철, "심바스타틴과 니카르디핀과의 약동학적 상호작용", 한국임상약학회지, 19(1), pp.32~36 (2009), 한국임상약학회
- Choi DH, "Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats", Eur J Durg Metabol, 34, pp.163~168 (2009)
- Grundy JS, "Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection", J Chromatogr B Biomed Appl, 654, pp.146~152 (1994)
- Rocci ML, "LAGRAN program for area and moments in pharmacokinetic analysis", Computer Programs in Biomedicine, 16, pp.203~209 (1983)
- Gottesman MM, "Biochemistry of multidrug resistance mediated by the multidrug transporter", Annu Rev Biochem, 62, pp.385~390 (1993)
- Ito K, "Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach", Pharm Res, 16, pp.225~231 (1999)